

Tessie 0.3 mg/ml - Oral solution

Authorised

- Tasipimidine sulfate

Product identification

Medicine name:

Tessie 0.3 mg/ml - Oral solution

Active substance:

Tasipimidine sulfate

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Tasipimidine sulfate

0.43 milligram(s) / 1.00 Bottle

Pharmaceutical form:

Oral solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM96

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Czechia , Denmark , Estonia , Finland , France , Germany , Hungary , Ireland , Latvia , Lithuania , Luxembourg , Netherlands , Norway , Poland , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Bottle (glass), Package_size:1 bottle + 1 oral syringe, Content:15 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Orion Corporation

Marketing authorisation date:

16/08/2021

Manufacturing sites for batch release:

Orion Corporation

Orion Corporation

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

16/08/2021

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 4/08/2026

[Download](#)

ema-puar-tessie-v-5427-par-en.pdf